These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11518088)

  • 21. Pharmacoeconomics of adverse drug reactions.
    Lundkvist J; Jönsson B
    Fundam Clin Pharmacol; 2004 Jun; 18(3):275-80. PubMed ID: 15147278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drugs and human memory (part 2). Clinical, theoretical, and methodologic issues.
    Ghoneim MM
    Anesthesiology; 2004 May; 100(5):1277-97. PubMed ID: 15114228
    [No Abstract]   [Full Text] [Related]  

  • 23. [Introduction to the theory of pharmaco-economics].
    Kurz X; Dresse A
    Rev Med Liege; 1998 May; 53(5):230-5. PubMed ID: 9689873
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potential biases in assessing the risks of pharmacotherapy due to mismeasurement of drug exposure.
    Leader S; Mallick R
    Clin Ther; 1998; 20(1):160-8; discussion 158-9. PubMed ID: 9522112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The mathematics of drug dose individualization should be built with random-effects linear models.
    Diaz FJ; de Leon J
    Ther Drug Monit; 2013 Apr; 35(2):276-7. PubMed ID: 23503456
    [No Abstract]   [Full Text] [Related]  

  • 26. Response to Diaz and de Leon "the mathematics of drug dose individualization should be built with random effects linear models".
    Holford NH; Buclin T
    Ther Drug Monit; 2013 Dec; 35(6):873-4. PubMed ID: 24263647
    [No Abstract]   [Full Text] [Related]  

  • 27. Pharmacology and aging.
    Vestal RF
    J Am Geriatr Soc; 1982 Mar; 30(3):191-200. PubMed ID: 7037916
    [No Abstract]   [Full Text] [Related]  

  • 28. Pharmacoeconomics of drug therapy for rheumatoid arthritis.
    Tugwell P
    Rheumatology (Oxford); 2000 Jun; 39 Suppl 1():43-7. PubMed ID: 11001379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. THE ECONOMICS OF ADVERSE DRUG REACTIONS--case studies.
    Visconti JA; Smith MC
    Ann Pharmacother; 2006 Mar; 40(3):529-36. PubMed ID: 16507611
    [No Abstract]   [Full Text] [Related]  

  • 30. State-dependent learning and its implications for treatment of drug-abusers.
    Ross SM; Schwartz CW
    Psychiatr Q; 1974; 48(3):368-73. PubMed ID: 4463399
    [No Abstract]   [Full Text] [Related]  

  • 31. Drugs with aging. Misperceptions about medications.
    Mayo Clin Health Lett; 2014 Dec; 32(12):7. PubMed ID: 26087529
    [No Abstract]   [Full Text] [Related]  

  • 32. Economic effects of clinical pharmacy interventions: a literature review.
    De Rijdt T; Willems L; Simoens S
    Am J Health Syst Pharm; 2008 Jun; 65(12):1161-72. PubMed ID: 18541687
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The cost of adverse drug reactions.
    Gautier S; Bachelet H; Bordet R; Caron J
    Expert Opin Pharmacother; 2003 Mar; 4(3):319-26. PubMed ID: 12614184
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Are adverse effects incorporated in economic models? An initial review of current practice.
    Craig D; McDaid C; Fonseca T; Stock C; Duffy S; Woolacott N
    Health Technol Assess; 2009 Dec; 13(62):1-71, 97-181, iii. PubMed ID: 20018146
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Economic analysis as an aid to subsidisation decisions: the development of Australian guidelines for pharmaceuticals.
    Henry D
    Pharmacoeconomics; 1992 Jan; 1(1):54-67. PubMed ID: 10147039
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Oral pentobarbital intake in rhesus monkeys: effects of drug concentration under conditions of food deprivation and satiation.
    Kliner DJ; Meisch RA
    Pharmacol Biochem Behav; 1989 Jan; 32(1):347-54. PubMed ID: 2734345
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discounting of health benefits in the pharmacoeconomic analysis of drug therapies: an issue for debate?
    Coyle D; Tolley K
    Pharmacoeconomics; 1992 Aug; 2(2):153-62. PubMed ID: 10146954
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Current issues with regard to single dose toxicity studies.
    Hashimoto M
    J Toxicol Sci; 1996 Dec; 21(5):417-20. PubMed ID: 9035048
    [No Abstract]   [Full Text] [Related]  

  • 39. Examining the quality of health economic analyses submitted to the Pharmaceutical Benefits Board in Sweden. The first year.
    Ramsberg J; Odeberg S; Engström A; Lundin D
    Eur J Health Econ; 2004 Dec; 5(4):351-6. PubMed ID: 15452738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Regulatory and Economic Considerations of Retinal Drugs.
    Shah AR; Williams GA
    Dev Ophthalmol; 2016; 55():376-80. PubMed ID: 26502165
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.